AbbVie entered into a voluntary agreement with the Trump administration, committing to invest $100 billion in research, development and manufacturing in the US over the next ten years[1][2]. The company is committed to offering lower Medicaid prices for its drugs and expanding direct-to-patient sales through the TrumpRx platform, which includes drugs such as Humira, Alphagan, Combigan and Synthroid[1][3]. In exchange, AbbVie received exemption from tariffs on pharmaceutical products and future price mandates for three years[5]. The agreement addresses all four of President Trump's drug pricing priorities[1]. AbbVie employs approximately 29,000 workers in the US and its medicines treat 16 million Americans annually[1]. The agreement is part of a broader effort by the Trump administration that has already signed more than ten major pharmaceutical companies, including Pfizer, Merck & Co. and Gilead Sciences[4].